Leash Bio
Unleashing machine learning to solve medicinal chemistry
A company transforming drug design by building a massive dataset of protein-molecule interactions to train machine learning models for identifying promising
The pitch
Leash Bio is transforming drug design by building a massive, proprietary dataset of protein-molecule interactions. The company has measured over 30 billion protein-molecule interactions and created 6.7 million ML-designed molecules through a dynamic, cyclical engine that continuously harnesses data, iterates machine learning, and refines its approach.
The company's innovative software enables rapid design of novel chemical matter more likely to have the right activities. Leash Bio operates internal drug discovery programs starting with two oncology targets and works with biopharma partners to explore new molecule opportunities. The company screens over 700 protein targets against millions of molecules at a capacity of 96 per week.
Under the hood
- 30 billion+ protein-molecule interactions measured
- 6.7 million ML-designed molecules made and tested
- Over 700 protein targets screened
- Screening capacity of 96 molecules per week
- Dynamic, cyclical ML iteration engine
- Rapid novel molecule design software
- Internal oncology drug programs
- Biopharma partnership support
Quick answers
What is Leash Bio's approach to drug discovery?
Leash Bio transforms drug design by building a massive proprietary dataset of protein-molecule interactions through screening millions of compounds against thousands of proteins to generate billions of data points. These data points are used to train advanced machine learning models that identify promising drug candidates. The company uses a dynamic, cyclical engine that continuously harnesses data, iterates machine learning, and refines its approach.
How many protein-molecule interactions has Leash Bio measured?
Leash Bio has measured over 30 billion protein-molecule interactions and created 6.7 million ML-designed molecules through testing and screening.
What targets is Leash Bio currently working on?
Leash Bio is developing new medicines starting with two targets in oncology through its internal programs. The company also works with biopharma partners to explore new molecule opportunities.
How many protein targets does Leash Bio screen?
Leash Bio screens over 700 protein targets against millions of molecules with a screening capacity of 96 molecules per week.
Leash Bio has a free listing. The owner can unlock the full profile with a paid launch for $5:
- Founder story (locked)
- Milestones (locked)
- Demo video (locked)
- Dofollow website link (locked)